742 related articles for article (PubMed ID: 25042139)
1. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Nambiar A; Lucas M
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
[TBL] [Abstract][Full Text] [Related]
2. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Cruz F; Nitti V
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
[TBL] [Abstract][Full Text] [Related]
3. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
[TBL] [Abstract][Full Text] [Related]
4. Chapter 6: Practical aspects of administration of onabotulinumtoxinA.
Rovner E
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S32-7. PubMed ID: 25042141
[TBL] [Abstract][Full Text] [Related]
5. Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.
Haab F
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S2-5. PubMed ID: 25042138
[TBL] [Abstract][Full Text] [Related]
6. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.
Apostolidis A; Rahnama'i MS; Fry C; Dmochowski R; Sahai A
Neurourol Urodyn; 2016 Feb; 35(2):293-8. PubMed ID: 26872570
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
[TBL] [Abstract][Full Text] [Related]
9. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin A for the Treatment of Overactive Bladder.
Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
[TBL] [Abstract][Full Text] [Related]
11. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
Ellsworth P; Travis M
Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
13. Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A.
Dolly JO; Lawrence GW
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S14-20. PubMed ID: 25042137
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin for the management of bladder dysfunction.
Schurch B
Drugs; 2006; 66(10):1301-18. PubMed ID: 16903766
[TBL] [Abstract][Full Text] [Related]
19. Use of botulinum toxin for genitourinary conditions: What is the evidence?
da Silva CM; Chancellor MB; Smith CP; Cruz F
Toxicon; 2015 Dec; 107(Pt A):141-7. PubMed ID: 26235907
[TBL] [Abstract][Full Text] [Related]
20. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
Harris MA; Harding C; Fulford S; Whiteway J
BJU Int; 2011 Apr; 107(7):1165; author reply 1165. PubMed ID: 21438980
[No Abstract] [Full Text] [Related]
[Next] [New Search]